Overview
Portfolio
More
Prospect Ventures
Portfolio
25+
Employees
N/A
Founded
N/A
AUM
N/A
Investment focus
Stages
No stages listed
Industries
No industries listedSources
Prospect Ventures
Portfolio
25+
Employees
N/A
Founded
N/A
AUM
N/A
Showing 13 of 13 matched portfolio companies
Andira Pharmaceuticals develops cannabinoid‑based therapeutics and medical devices that use synergistic cannabinoid combinations to improve outcomes for post‑surgical pain, chronic wounds, and early‑stage breast cancer. Their pipeline includes a transdermal analgesic (AND‑254), a localized breast‑cancer therapy (AND‑259), and the Silvanex™ platform, a triple‑synergy silver‑cannabinoid formulation that provides broad antimicrobial activity and promotes tissue repair.
Funding: $393.1K
Rough estimate of the amount of funding raised
Funding: $393.1K
Rough estimate of the amount of funding raised
ERC System develops a hybrid-electric aviation platform capable of vertical take-off and landing (eVTOL). This platform is engineered for cost-efficient operation, significantly outperforming helicopters in operating costs. The system provides extended range and substantially faster travel times compared to ground transportation for critical missions.
Fin provides zero-emission parcel delivery and logistics services using an all-electric fleet of vans and e-cargo bikes, optimizing urban logistics through city center micro-fulfilment hubs. This approach reduces delivery costs and eliminates carbon emissions associated with last-mile logistics for e-commerce brands.
Funding: $28.0M
Rough estimate of the amount of funding raised
Funding: $28.0M
Rough estimate of the amount of funding raised
Gen+ is a digital platform that provides leadership and meta-skills education for learners aged 9-14 and their teachers, utilizing a blended learning approach that combines online and in-person instruction. The program addresses the lack of standardized skills development in schools by equipping students with essential, transferable skills necessary for success in learning, work, and life.
Funding: $100.7K
Rough estimate of the amount of funding raised
Funding: $100.7K
Rough estimate of the amount of funding raised
HARM provides an AI-powered platform for individuals experiencing harm to quickly access immediate, trusted support. The system intelligently identifies the nature of the reported harm and routes users directly to appropriate, city-approved advocacy, legal, or housing resources. This streamlined process eliminates confusion while generating de-identified data insights to help municipal leaders optimize community support services.
Kythera Labs develops the Wayfinder platform, which utilizes machine learning to enhance and analyze healthcare claims data, transforming it into accurate insights for market dynamics and patient behavior. This platform addresses the challenge of extracting actionable intelligence from complex healthcare datasets, enabling organizations to make informed strategic decisions without the need for extensive data infrastructure.
Funding: $29.2M
Rough estimate of the amount of funding raised
Funding: $29.2M
Rough estimate of the amount of funding raised
Lü offers an interactive audiovisual system that turns any wall in a gym, classroom, or community hall into a high‑definition, touch‑responsive canvas for active learning. Combining ceiling‑mounted projectors, motion‑sensing cameras, lighting, and spatial audio, the platform delivers 45+ curriculum‑aligned apps and customizable content for 5‑12‑year‑olds, supporting 25‑50+ children simultaneously. Schools and recreation centers can purchase the hardware outright and add a Lü+ subscription for premium apps and ongoing content updates.
Funding: $50.0K
Rough estimate of the amount of funding raised
Funding: $50.0K
Rough estimate of the amount of funding raised
MarinaTex produces biodegradable flexible films made from sustainable materials that can be composted at home. This product provides a compostable alternative to traditional plastics, significantly reducing plastic waste and its environmental impact.
Funding: $216.3K
Rough estimate of the amount of funding raised
Funding: $216.3K
Rough estimate of the amount of funding raised
Merge offers a single‑tenant, API‑first integration platform that lets product and engineering teams quickly connect to over 200 pre‑built third‑party services such as file storage, ATS, HRIS, and ticketing. Its unified API, embedded Merge Link UI, and real‑time data sync handle authentication, data normalization, security, and compliance, while observability tools provide proactive monitoring of integration health.
Funding: $55.0M
Rough estimate of the amount of funding raised
Funding: $55.0M
Rough estimate of the amount of funding raised
Neomed is a marketplace that facilitates the secure exchange of medical records among hospitals, laboratories, and physicians, enhancing interoperability and data accessibility. This platform addresses the inefficiencies and communication barriers in healthcare data management, improving patient care coordination and operational workflows.
NOVA is a platform that connects creative professionals with job opportunities by allowing users to showcase their portfolios and post job listings tailored to specific project needs. It addresses the challenge of finding qualified talent quickly in the creative industry, having generated over $10 million for creatives and facilitated 17,000 job postings across more than 500 cities globally.
Funding: $1.8M
Rough estimate of the amount of funding raised
Funding: $1.8M
Rough estimate of the amount of funding raised
This company appears to be developing medical technology or services, though specific details are not yet available on their site. They are currently preparing to launch their official online presence. Further information will be provided upon the site's completion.
Funding: $1.7M
Rough estimate of the amount of funding raised
Funding: $1.7M
Rough estimate of the amount of funding raised
Viamet develops novel therapies by leveraging its expertise in metalloenzyme chemistry and biology. The company's clinical portfolio focuses on treating chronic and life-threatening fungal infections, with additional research in oncology and orphan diseases. Viamet designs drug candidates to offer improved safety and efficacy profiles compared to existing treatments.
Showing 12 of 12 unmatched portfolio companies